Opinion|Videos|March 28, 2025
Recent Updates in the Management Advanced NSCLC with HER2 or NRG1 Alterations
Panelists discuss how emerging data on novel HER2-targeted agents, including Beamion LUNG-1 (zongertinib) and SOHO-1 (BAY 2927088), show promise for advanced non–small cell lung cancer (NSCLC). Additionally, the eNRGy trial and FDA approval of zenocutuzumab for NRG1 fusion–positive non–small cell lung cancer (NSCLC) offers new treatment avenues. Patient selection will depend on genetic profiling and treatment efficacy
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are your thoughts on the emerging data surrounding novel HER2-targeted agents, and how may they impact the future treatment landscape for NSCLC?
- Beamion LUNG-1 (zongertinib): Ruiter G, et al. WCLC 2024. Abs PL04.04
- SOHO-1 (BAY 2927088): Le X, et al. WCLC 2024. Abs PL04.03
- Briefly comment on the eNRGy trial andFDA approval (December 2024) ofzenocutuzumab for advanced, unresectable, or metastatic NSCLC harboring an NRG1 gene fusion. (Schram AM, et al. ESMO 2023. Abs 1315MO; FDA.gov, FDA approves zenocutuzumab for NSCLC)
- How might you incorporate this novel therapy into your clinical practice, and what factors guide your patient selection?
Advertisement
Related to this article
An NDA seeks FDA approval of savolitinib plus osimertinib for EGFR-mutated NSCLC with MET overexpression or amplification after EGFR TKI therapy.
Daiichi Sankyo and Merck withdrew the I-DXd BLA in ES-SCLC after FDA discussions found phase 2 IDeate-Lung01 data insufficient for accelerated approval.
The addition of the β-catenin pathway inhibitor tegavivint to osimertinib produced deep responses in a phase 1b study in first-line EGFR-mutated NSCLC.
The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.
The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The phase 3 REZILIENT3 trial met its primary end point at a pre-specified interim analysis, with a median PFS of 14.5 months and a 65.0% ORR.
The FDA has cleared an sNDA updating the taletrectinib (Ibtrozi) label with new DOR data in TKI-naive patients with locally advanced or metastatic ROS1-positive NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
China's NMPA Approves Pirtobrutinib Across CLL
3
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
4
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
5